You are here: Home » Markets » News
Business Standard

Ranbaxy Laboratories rebounds over 6% from intra-day low

The stock moved higher by 4% to Rs 625, bouncing back 6.5% from intra-day low of Rs 587 on BSE.

SI Reporter  |  Mumbai 

Shares of Ranbaxy Laboratories have moved higher by 4% to Rs 625, bouncing back 6.5% from intra-day low on BSE, on back of heavy volumes.

The stock opened at Rs 597 and touched a low of Rs 587 in early trade on BSE. The trading volumes on the counter more than doubled with a combined 3.2 million shares changing hands till 1148 hours on NSE and BSE.

Meanwhile, shares of generic drug maker had dipped 14% from its record closing high of Rs 681 on November 11, after the US Food & Drug Administration (US FDA) revoked Ranbaxy’s six-month exclusivity for Nexium and Valcyte.

According to Reuters report, a US court has denied a request by drugmaker Ranbaxy Laboratories to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed.

Ranbaxy and the FDA have until Nov 21 to submit a schedule for further proceedings in the case, the filing showed, added report.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, November 20 2014. 11:56 IST